

THROMBOSIS RESEARCH

SPECIAL ISSUE:

In Honour of Sir John Vane, F.R.S., Nobel Laureate,
the Discoverer of the Mechanism of Action of Aspirin
Krakow, 31 May–3 June 2003

GUEST EDITORS:

R.J. Gryglewski, W. Uracz

Also available on

SCIENCE @ DIRECT®

www.sciencedirect.com

P E R G A M O N



CONTENTS

SPECIAL ISSUE: In Honour of Sir John Vane, F.R.S., Nobel Laureate, the Discoverer of the Mechanism of Action of Aspirin

<i>Editorial</i>	
Editorial	
by R.J. Gryglewski (Cracow, Poland)	253
ORIGINAL ARTICLES	
The mechanism of action of aspirin (<i>Review</i>)	
by J.R. Vane and R.M. Botting (London, UK)	255
Studies on the mechanism of action of anti-inflammatory drugs. A paper in honour of John Vane	
by R.J. Flower (London, UK)	259
Variants of cyclooxygenase-1 and their roles in medicine (<i>Review</i>)	
by D.L. Simmons (Provo, UT, USA)	265
COX-1 and COX-3 inhibitors	
by R. Botting (London, UK)	269
Control of COX-2 and iNOS gene expressions by aspirin and salicylate	
by K.K. Wu (Houston, TX, USA)	273
TNF α regulates renal COX-2 in the rat thick ascending limb (TAL) (<i>Review</i>)	
by N.R. Ferreri, J.C. McGiff (Valhalla, NY, USA), C.P. Vio (Santiago, Chile) and M. A. Carroll (Valhalla, NY, USA)	277
Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease (<i>Review</i>)	
by P. Patrignani (Chieti, Italy)	281
Obligatory role of lipid mediators in platelet-neutrophil adhesion	
by S. Chłopicki, M. Lomnicka and R.J. Gryglewski (Cracow, Poland)	287
COX-2 lack of function in hypoxia-induced ocular surface inflammation	
by M.L. Schwartzman, A. Bonazzi, P. Mieczal, A. Mezentsev, N.G. Abraham and M.W. Dunn (Valhalla, NY, USA)	293
Effects of phenacetin and its metabolite <i>p</i> -phenetidine on COX-1 and COX-2 activities and expression in vitro	
by E. Kankuri, E. Solatunturi and H. Vapaatalo (Helsinki, Finland)	299
Heme oxygenase attenuated angiotensin II-mediated increase in cyclooxygenase activity and decreased isoprostane F $_{2\alpha}$ in endothelial cells	
by N.G. Abraham (Valhalla, NY, USA)	305
Activation of nuclear receptors by prostaglandins	
by T. Ide, K. Egan, L.C. Bell-Parikh and G.A. FitzGerald (Philadelphia, PA, USA)	311
Effect of aspirin on constitutive nitric oxide synthase and the bioavailability of NO	
by M. Madajka, M. Korda, J. White and T. Malinski (Athens, OH, USA)	317
Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats	
by R.J. Gryglewski, J. Święs, W. Uracz, S. Chłopicki, E. Marcinkiewicz (Cracow, Poland)	323
Aspirin and the fibrinolytic response	
by W. Buczek, A. Mogielnicki, K. Kramkowski and E. Chabielska (Mickiewicza, Poland)	331
COX and the control of the pulmonary circulation	
by R.S. Sprague, A.H. Stephenson, J.J. Olearczyk and A.J. Lonigro (St. Louis, MO, USA)	335
Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension	
by M. Jastrzębska, I. Gorący and M. Naruszewicz (Szczecin, Poland)	339



PUBLISHED STATE OF THE ART ARTICLES

THROMBOSIS
RESEARCH

	<i>Year:Volume:Issue</i>		<i>Year:Volume:Issue</i>
<i>Sadaaki Iwanaga, Toshiyuki Miyata, Fuminori Tokunaga and Tatsushi Muta</i> Molecular mechanisms of hemolymph clotting system in <i>Limulus</i>	1992;68:1	<i>Björn Dahlbäck</i> The protein C anticoagulant system: Inherited defects as basis for venous thrombosis	1995;77:1
<i>Milton T. Stubbs and Wolfram Bode</i> A player of many parts: The spotlight falls on thrombin's structure	1993;69:1	<i>Douglas A. Triplett</i> Antiphospholipid antibodies: Laboratory detection and clinical relevance	1995;78:1
<i>Anders Hamsten</i> The hemostatic system and coronary heart disease	1993;70:1	<i>Lars Chr. Petersen, Sanne Valentin and Ulla Hedner</i> Regulation of the extrinsic pathway system in health and disease: The role of factor VIIa and tissue factor pathway inhibitor	1995;79:1
<i>Tor Ny, Xiao-Rong Peng and Monica Ohlsson</i> Hormonal regulation of the fibrinolytic components in the ovary	1993;71:1	<i>Bo Forslind</i> The skin—upholder of physiological homeostasis. A physiological and (bio)physical study program	1995;80:1
<i>Matthew M. Rees and George M. Rodgers</i> Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis	1993;71:5	<i>Eric Camerer, Anne-Brit Kolstø and Hans Prydz</i> Cell biology of tissue factor, the principal initiator of blood coagulation	1996;81:1
<i>Yanina T. Wachfogel, Raul A. DeLa Cadena and Robert W. Colman</i> Structural biology, cellular interactions and pathophysiology of the contact system	1993;72:1	<i>Michael J. Davies</i> The contribution of thrombosis to the clinical expression of coronary atherosclerosis	1996;82:1
<i>Elsbeth B. Smith and W. Douglas Thompson</i> Fibrin as a factor in atherogenesis	1994;73:1	<i>Birger Blombäck</i> Fibrinogen and fibrin—proteins with complex roles in hemostasis and thrombosis	1996;83:1
<i>Fritz Markwardt</i> The development of hirudin as an antithrombotic drug	1994;74:1	<i>Gian Franco Gensini, Serena Micheli, Domenico Prisco and Rosanna Abbate</i> Menopause and risk of cardiovascular disease	1996;84:1
<i>Ulf Lindahl, Kerstin Lidholt, Dorothe Spillman and Lena Kjellén</i> More to "heparin" than anticoagulation	1994;75:1	<i>Bjarne Østerud</i> A global view on the role of monocytes and platelets in atherogenesis	1997;85:1
<i>Akikazu Takada, Yumiko Takada and Tetsumei Urano</i> The physiological aspects of fibrinolysis	1994;76:1	<i>Jeanine M. Walenga, Walter P. Jeske, Lucienne Bara, Meyer M. Samama and Jawed Fareed</i> Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide	1997;86:1
<i>Margarita Rodrigues and Helmut Sinzinger</i> Platelet labeling—methodology and clinical applications	1994;76:5		

(Continued on next page)